User:Mr. Ibrahem/Ropinirole
Clinical data | |||
---|---|---|---|
Trade names | Requip, Repreve, Ronirol, others | ||
AHFS/Drugs.com | Monograph | ||
MedlinePlus | a698013 | ||
Pregnancy category |
| ||
Routes of administration | By mouth | ||
Legal status | |||
Legal status |
| ||
Pharmacokinetic data | |||
Bioavailability | 50%[1] | ||
Metabolism | Liver (CYP1A2)[1] | ||
Elimination half-life | 5-6 hours[1] | ||
Identifiers | |||
| |||
Chemical and physical data | |||
Formula | C16H24N2O | ||
Molar mass | 260.381 g·mol−1 | ||
3D model (JSmol) | |||
| |||
| |||
(verify) |
Ropinirole, sold under the brand name Requip among others, is a medication used to treat Parkinson's disease (PD) and restless legs syndrome (RLS).[3] In PD the dose needs to be adjusted to the effect and treatment should not be suddenly stopped.[3] It is taken by mouth.[4]
Common side effects include sleepiness, vomiting, and dizziness.[4] Serious side effects may include pathological gambling, low blood pressure with standing and hallucinations.[4][3] Use in pregnancy and breastfeeding is of unclear safety.[5] It is a dopamine agonist and works by triggering dopamine D2 receptors.[4]
It was approved for medical use in the United States in 1997.[4] It is available as a generic medication.[3] A month supply in the United Kingdom costs the NHS about £34 per month as of 2019.[3] In the United States the wholesale cost of this amount is about US$7.90.[6] In 2017, it was the 108th most commonly prescribed medication in the United States, with more than six million prescriptions.[7][8]
References[edit]
- ^ a b c Tompson, Debra J.; et al. (2007). "Steady-State Pharmacokinetic Properties of a 24-Hour Prolonged-Release Formulation of Ropinirole: Results of Two Randomized Studies in Patients with Parkinson's Disease". Clinical Pharmacokinetics. 29 (12): 2654–66. doi:10.1016/j.clinthera.2007.12.010. PMID 18201581.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 6 September 2020.
- ^ a b c d e British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 419–420. ISBN 9780857113382.
- ^ a b c d e "Ropinirole Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
- ^ "Ropinirole Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.
- ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
- ^ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
- ^ "Ropinirole Hydrochloride - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.